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Bladder cancer is the most common malignancy of the urinary
tract, and the fourth or fifth leading cause of cancer-related deaths
of men in Western industrialized countries. The prognosis of
patients with metastatic bladder cancer is still extremely poor in
spite of the recent therapeutic advances, such as improved surgical
techniques and perioperative combination chemotherapy
(Thrasher and Crawford, 1993). It is thus important to investigate
the mechanism of metastasis of bladder cancer, in order to develop
novel therapeutic strategies and consequently improve the survival
of patients with advanced bladder cancer.
Apoptosis is a crucial event in various physiological processes,
such as embryogenesis, organ development and cell proliferation,
as well as pathological processes including autoimmune disease
and cancer development (Ellis et al, 1991). These phenomena are
regulated by several genes and, among them, Bcl-2, initially iden-
tified as the proto-oncogene translocated to the immunoglobulin
heavy chain locus in human follicular B-cell lymphomas, is recog-
nized as one of the most potent inhibitors of apoptosis induced by
a wide variety of stimuli, such as radiation, chemotherapeutic
agents and growth factor deprivation (Tsujimoto et al, 1985).
Consistently, many investigators have demonstrated that overex-
pression of Bcl-2 closely correlates with the progression of various
human malignancies, including bladder cancer (Gallo et al, 1996;
King et al, 1996). Furthermore, recent studies have suggested that
prolonged survival of cancer cells may contribute to promote their
metastatic potential (Inbal et al, 1997; Shtivelman, 1997; Takaoka
et al, 1997).
From these findings, we speculate that Bcl-2 confers a benefit
for the progression of bladder cancer through the inhibition of
apoptosis induced by a variety of obstacles that cancer cells may
confront after detachment from their primary origin; hence, we
report here the effect of Bcl-2 expression on the metastatic process
of human bladder cancer cells in both in vitro and in vivo experi-
mental models.
MATERIALS AND METHODS
Tumour cell lines
The human bladder cancer cell line KoTCC-1 was established in
our laboratory (Miyake et al, 1997), and the Bcl-2-transfected
KoTCC-1 cell lines (KoTCC-1/BH1 to KoTCC-1/BH4) and the
control vector only-transfected cell line (KoTCC-1/C) were gener-
ated by the liposome-mediated gene transfer method in our
previous study (Miyake et al, 1998a). These cell lines were main-
tained in RPMI-1640 supplemented with 10% fetal calf serum.
Northern blot analysis
Total RNA of each cell line was extracted by the acid–
guanidinium thiocyanate–phenol–chloroform method. Aliquots
of 30 mg of RNA were separated by electrophoresis on 1.2%
agarose–formaldehyde gels, capillary-transferred to a nylon
membrane overnight, and cross-linked with ultraviolet irradiation.
The filters were hybridized at 42°C overnight with a human Bcl-2
cDNA probe labelled with 32P-deoxycytidinetriphosphate by
random primer labelling. The filters were then washed in 0.5%
standard saline citrate and 0.1% sodium dodecyl sulphate (SDS)
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at – 80°C. After stripping, the membranes were rehybridized with
a human glyceraldehyde phosphate dehydrogenase (GAPDH)
cDNA probe.
Cell proliferation assay
To compare the in vitro proliferation of KoTCC-1 sublines, 5 ´ 103
cells of each cell line were seeded in each well of 12-well plates,
and the number of cells in each cell line was counted daily by
triplicate.
In vitro tumour cell invasion assay
Tumour cell invasion was measured with a membrane invasion
culture system (Albini et al, 1987) in a minor modification. Briefly,
we used polycarbonate filters with a pore size of 8 mm, coated with
varying amounts of basement membrane Matrigel (Becton
Dickinson Labware, Lincoln Park, NJ, USA). The coated filters
were placed in Boyden chambers, in the upper compartment of
which 1 ´ 105 cells of each cell line were suspended in Dulbecco’s
modified Eagle’s medium (DMEM/F-12 and in the lower compart-
ment of which fibronectin (25 mg ml-1) diluted with DMEM/F-12
was added as a chemoattractant. After 72 h incubation, the filters
were fixed in methanol and stained with Giemsa solution. Cells that
had migrated to the lower surface of the filters were counted manu-
ally at a 200 ´ magnification and the mean numbers of cells per
field in three random fields was recorded. Similarly, cell motility
was also assessed by using the Boyden chambers without Matrigel.
Each assay was performed in triplicate.
Limiting dilution assay
The colonization activity and cell viability of KoTCC-1 sublines
under solitary cell conditions were evaluated with a limiting dilu-
tion assay (Takaoka et al, 1997) in a minor modification. Briefly,
1 ´ 102 cells of each cell line were seeded with one cell per well in
96-well microtiter plates and cultured in RPMI-1640 supple-
mented with 2% fetal calf serum. After 10 days of culture,
numbers of appeared colonies were counted. Each assay was
performed in triplicate.
Cell survival assay in suspension
The cell viability of KoTCC-1 sublines under the condition
lacking contact with substrate was examined by the previously
described method (Nikiforov et al, 1997). Briefly, 5 ´ 105 cells of
each cell line were suspended in 30 ml of RPMI-1640 supple-
mented with 2% fetal calf serum, and then added into 50 ml
polypropylene tubes. The tubes were subjected to gentle rocking
on a rocking platform in a 37°C room in an atmosphere of 5%
carbon dioxide for the indicated periods. After completion of the
assay, cells were collected from the tubes and replaced in fresh
medium onto tissue culture dishes. After 24 h of culture, the cell
viability was quantitated by the MTT assay according to a previ-
ously reported protocol (Miyake et al, 1998b). Each assay was
performed in triplicate. In addition, DNA was isolated from each
cell line subjected to 24 h floating, and DNA fragmentation
analysis was performed as described previously (Miyake et al,
1998a).
Animal studies
Athymic nude mice (Balb/c nu/nu females, 6–8 weeks old) were
purchased from CLEA Japan, Inc. (Tokyo, Japan), and housed in a
controlled environment at 22°C on a 12 h light, 12 h dark cycle.
Animals were maintained in accordance with the NIH Guide for
the Care and Use of Laboratory Animals. Each experimental group
consisted of 10 mice. Each of the tumour cell lines was
trypsinized, washed twice with phosphate-buffered saline (PBS),
and injected subcutaneously with 1 ´ 106 cells in the flank, intra-
venously with 1 ´ 106 cells in the tail vein or directly administered
1 ´ 106 cells into the bladder wall, as previously described (Dinney
et al, 1995).
The growth of subcutaneous tumour was successively measured
with a caliper. The greatest length of a tumour mass (a) and the
width perpendicular to it (b) were measured every 5 days, and the
tumour size was reported as a ´ b. Eight weeks after the injection
of tumour cells in the tail vein, or 4 weeks after that in the bladder
wall, the mice were sacrificed and the presence of tumour nodules
was macroscopically examined in all abdominal and thoracic
internal organs. The organs with tumour nodules were removed,
and the number of surface tumour nodules was counted. The
termination points of these studies were determined according to
the preliminary experiments in order that tumour-related deaths
may not occur before sacrifice.
Statistical analysis
All of the data were evaluated by the Student’s t-test. The levels of
significance were set at P < 0.05.
RESULTS
Northern blot analysis of Bcl-2 mRNA levels among
KoTCC-1 sublines
Expression levels of the Bcl-2 mRNA in KoTCC-1/P, KoTCC-1/C
and the Bcl-2-transfected cell lines (KoTCC-1/BH1 to KoTCC-
1/BH4) were analysed by Northern blotting. As shown in Figure 1,
the Bcl-2 mRNA were highly expressed in four Bcl-2 transfected
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Figure 1 Northern blot analysis of Bcl-2 mRNA in KoTCC-1 and Bcl-2-
transfected cell lines. Total RNA was isolated and 30 mg of RNA was
electrophoresed in 1.2% agarose gels and blotted onto a nylon membrane.
The membrane was hybridized with 32P-labelled Bcl-2 cDNA specific for
human Bcl-2 mRNA (A). After the removal of the radiolabelled probe, the
membrane was rehybridized with GAPDH cDNA probe (B) to check the
relative amounts of mRNA loaded on to the gel. Lane 1, KoTCC-1/P, parental
cell line of KoTCC-1; Lane 2, KoTCC-1/C, vector only-transfected cell line;
Lane 3, KoTCC-1/BH1; Lane 4, KoTCC-1/BH2; Lane 5, KoTCC-1/BH3; Lane
6, KoTCC-1/BH4. KoTCC-1/BH1 – KoTCC-1/BH4 are Bcl-2-transfected cell
linesclones at almost the same levels; in contrast, no detectable Bcl-2
mRNA was expressed in either KoTCC-1/P or KoTCC-1/C. The
four Bcl-2-transfected clones showed almost the same results in
the subsequent experiments; therefore, we hereafter report only the
data of KoTCC-1/P, KoTCC-1/C, KoTCC-1/BH1 and KoTCC-
1/BH2.
Effects of Bcl-2 overexpression on in vitro malignant
phenotypes of KoTCC-1 cells
Cell proliferation, invasive ability and cell motility are crucial
factors for cancer metastasis; therefore, we initially determined
whether cell proliferation, invasive ability and cell motility are
altered by the overexpression of Bcl-2. There was no significant
difference in cell proliferation in vitro among KoTCC-1/P,
KoTCC-1/C, KoTCC-1/BH1 and KoTCC-1/BH2. Similar levels
of the invasive potential and cell motility among KoTCC-1
sublines were also demonstrated by using trans-well culture
chamber systems (Figure 2).
In vitro anti-cell death activity of KoTCC-1 sublines
We then evaluated the relationship between the overexpression of
Bcl-2 and the anti-cell death activity under anchorage-independent
conditions among KoTCC-1 sublines by two different methods
(i.e. limiting dilution assay and cell survival assay in suspension).
As shown in Table 1, KoTCC-1/BH1 and KoTCC-1/BH2 exhib-
ited significantly enhanced growth in limiting-dilution cultures
Bcl-2 and metastasis in bladder cancer 1653
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Figure 2 (A) In vitro proliferation of KoTCC-1 and transfected clones of
KoTCC-1. KoTCC-1/P cells, KoTCC-1 parental cell line; KoTCC-1/C cells
transfected with control vector; KoTCC-1/BH1 cells transfected with the bcl-2
gene (these cells expressed high levels of Bcl-2 protein); KoTCC-1/BH2 cells
transfected with the bcl-2 gene (these cells expressed nearly same levels of
Bcl-2 as KoTCC-1/BH1). Five thousand cells of each cell line were seeded in
12-well plates. The cells were counted daily in triplicate. Bars represent
standard deviations. (B) Measurement of in vitro invasive abilities of KoTCC-1
sublines. Each cell line was seeded at 1 ´ 105 per well in Boyden chambers.
Chambers were incubated for 72 h in serum free DMEM/F-12, then numbers
of cells that had migrated to lower surface of filters through reconstituted
basement membrane Matrigel was counted at a 200 ´ magnification. Column
and bars represent mean and standard deviation. (C) Measurement of cell
motilities of KoTCC-1 sublines. Cell motility of each cell line was assessed by
using Boyden chamber without Matrigel under the same condition as
described above. Column and bars represent mean and standard deviation
Table 1 Colonization of KoTCC-1 sublines upon limiting dilution
Cell linea Colony formation (%)b
KoTCC-1/P 42.7 ± 5.2c
KoTCC-1/C 44.8 ± 6.3
KoTCC-1/BH1 91.7 ± 7.2d
KoTCC-1/BH2 88.5 ± 9.8d
aCells (1 ´ 102) were diluted with RPMI plus 2% FCS and seeded into 96-well
plates. The cells were cultured for 10 days. bPercentage of the wells in which
cells grew was calculated. cMean ± S.D. dThe mean % of colony formation
was significantly different from that of KoTCC-1/P and KoTCC-1/C at
P < 0.01 (Student’s t-test).
Table 2 Cell viability of KoTCC-1 sublines in suspension
Surviving cells (%)b
Cell linea 24 h 48 h
KoTCC-1/P 52.4 ± 9.2c 23.7 ± 7.7
KoTCC-1/C 56.5 ± 8.3 26.8 ± 8.3
KoTCC-1/BH1 93.6 ± 8.8d 59.3 ± 7.2d
KoTCC-1/BH2 90.5 ± 8.3d 55.5 ± 6.8d
aCells (5 ´ 105) were suspended in RPMI plus 2% FCS and subjected to 24
or 48 h floating. bPercentage of the viable cells normalized to the values
obtained from control cells which were not subjected to floating. cMean ± s.d.
dThe mean % of surviving cells was significantly different from that of
KoTCC-1/P and KoTCC-1/C at P < 0.01 (Student’s t-test).compared to KoTCC-1/P and KoTCC-1/C. The analysis of cell
survival in the floating assay also demonstrated that the Bcl-2
transfectants had a powerful survival advantage in suspension
compared to parental and control cells (Table 2). Furthermore, we
performed DNA fragmentation analysis of each cell line subjected
to 24-h floating in order to assess the apoptotic feature more
definitely. The characteristic DNA ladders were observed in
KoTCC-1/P and KoTCC-1/C but not in KoTCC-1/BH1 and
KoTCC-1/BH2 (Figure 3).
In vivo malignant potential of KoTCC-1 sublines
To examine the in vivo effects of Bcl-2 overexpression on tumour
growth, 1 ´ 106 cells of each cell line were injected subcutaneously
in the right flank of nude mice. There was no significant difference
in tumour growth in vivo among KoTCC-1/P, KoTCC-1/C,
KoTCC-1/BH1 and KoTCC-1/BH2 (Figure 4).
To investigate the effect of Bcl-2 overexpression on tumour
progression, we injected 1 ´ 106 cells of each cell line into the tail
vein or bladder wall. The mice were sacrificed 8 weeks after the
intravenous injection, at which time we found that KoTCC-1/BH1
and KoTCC-1/BH2 had formed more than three times as many
tumour nodules in lungs as had KoTCC-1/P and KoTCC-1/C
(Table 3). The size of tumours in the lung were small (i.e. less than
2 mm), but could be clearly observed as a white nodule. Similarly,
more marked differences were observed in tumour progression
among KoTCC-1 sublines 4 weeks after the orthotopic implanta-
tion of each cell line; that is, as shown in Table 4, the incidence of
retroperitoneal lymph node metastasis, mesenteric lymph node
metastasis and haemorrhagic ascites in KoTCC-1/BH1 and
KoTCC-1/BH2 were significantly higher than those in KoTCC-
1/P and KoTCC-1/C. However, none of the primary tumours
formed by KoTCC-1 sublines showed the symptoms of invasion
into normal surrounding tissues, and there was no significant
difference in the weights of the primary tumours among the
KoTCC-1 sublines.
DISCUSSION
The process of cancer metastasis consists of multiple steps and its
regulation is extremely complicated (Fidler and Balch, 1987;
Miyake et al, 1996). During metastasis, cancer cells detach from
the primary origins in the body and must survive without adequate
cell-to-cell or cell-to-substrate contact in the circulation (Takaoka
et al, 1997; Nikiforov et al, 1997). Bcl-2 is the prototype of a novel
class of oncogenes that contributes to neoplastic cell growth not
by accelerating the rate of cellular proliferation but rather by
enhancing the tumour cell survival through the inhibition of apop-
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Figure 3 DNA fragmentation analysis of KoTCC-1 sublines after 24 h of the
floating assay. The isolated DNA was electrophoresed in a 2% agarose gel
and stained with ethidium bromide. Lane 1, KoTCC-1/P; Lane 2, KoTCC-1/C;
Lane 3, KoTCC-1/BH1; Lane 4, KoTCC-1/BH2. M = molecular weight
markers (1 kb ladder; Life Technologies, Inc., Gaithersburg, MD, USA)
Table 3 Lung colonization by KoTCC-1 sublines injected into the tail vein of
nude mice
Cell linea No. of tumour nodules in the lungb
KoTCC-1/P 10.4 ± 5.2c
KoTCC-1/C 12.5 ± 4.1
KoTCC-1/BH1 39.6 ± 9.5d
KoTCC-1/BH2 42.7 ± 8.4d
aCells (1 ´ 106) were injected into the tail vein of nude mice. The mice were
killed 8 weeks after injection. bThe number of surface tumour nodules in the
lung was determined. cMean ± s.d. dThe mean number of tumour nodules
was significantly different from that of KoTCC-1/P and KoTCC-1/C at P <
0.01 (Student’s t-test).
Table 4 Tumour progression by KoTCC-1 sublines injected into the bladder wall of nude mice
Incidence of metastasis (%)a
Retroperitoneal lymph Intra-abdominal lymph Incidence of Weight of the
Cell linec node metastasis node metastasis haemorrhagic ascites (%)b primary tumour
(mg)
KoTCC-1/P 5/10 (50) 2/10 (20) 0/10 (0) 32.2 ± 4.5d
KoTCC-1/C 6/10 (60) 2/10 (20) 0/10 (0) 34.1 ± 6.1
KoTCC-1/BH1 10/10 (100)e 7/10 (70)e 5/10 (50)e 30.9 ± 4.8
KoTCC-1/BH2 10/10 (100)e 8/10 (80)e 5/10 (50)e 33.6 ± 9.4
aNumber of mice with tumour/number of injected mice. bNumber of mice with haemorrhagic ascites/number of injected mice. cCells (1 ´ 106) were injected into
the bladder wall. The mice were killed 4 weeks after injection. dMean ± s.d. eThe incidences of metastasis or haemorrhagic ascites were significantly different
from that of KoTCC-1/P and KoTCC-1/C at P < 0.01 (Student’s t-test).tosis (Tsujimoto et al, 1985; Miyake et al, 1998a). Therefore, we
hypothesize that Bcl-2 overexpression may contribute to prolong
cancer cell survival against obstacles encountered in that process
and ultimately thereby promote metastasis. We thus investigated
the correlation of Bcl-2 overexpression with in vivo malignant
potential by using the Bcl-2-transfected human bladder cancer cell
lines (Miyake et al, 1998a).
Initially in order to rule out possibilities that in vitro malignant
phenotypes of KoTCC-1 cells were enhanced by the overexpres-
sion of Bcl-2, we compared cell proliferation, invasive ability and
cell motility among parental cells, control cells and the Bcl-2
transfectants. As expected, no significant differences were
observed among these cell lines in the in vitro phenotypes we
examined. We then investigated the effect of Bcl-2 overexpression
on the anti-cell death activity under anchorage-independent condi-
tions by limiting dilution assay and cell survival assay in suspen-
sion. In both assays, the Bcl-2 transfectants exhibited significantly
superior viability in comparison with control and parental cells.
These in vitro findings strongly suggest that Bcl-2 may give
enhanced ability to survive under anchorage-independent condi-
tions like those cancer cells encounter in circulation during
metastatic formation.
We next demonstrated that the Bcl-2 transfectants showed more
extensive malignant progression than parental and control cells by
using the intravenous and orthotopic tumour cell injection models.
These data revealed that the in vivo tumour progression of these
cell lines was closely correlated with their in vitro anti-cell death
activity under anchorage-independent conditions. In addition,
there were no significant differences in tumour growth among
these cell lines, when they were implanted in either ectopic (sub-
cutaneous) or orthotopic (bladder) organs. We also showed that no
remarkable differences in in situ apoptotic features among sub-
cutaneous and bladder tumours formed by these cell lines by the
terminal deoxynucleotidyl transferase-mediated deoxyuridine
5¢-triphosphate nick and labelling (TUNEL) staining (data not
shown). Considering these findings, we conclude that the phenom-
enon of the enhanced anti-apoptotic activity may not be entirely
responsible for the enhanced in vivo malignant potential of the
Bcl-2-transfected cells, but there is no doubt that anti-cell death
activity is involved in promoting the tumour progression in vivo.
Recent studies have revealed that several molecules, including
p53 (Nikiforov et al, 1997), DAP kinase (Inbal et al, 1997), BAG-
1 (Takaoka et al, 1997) and CC3 (Shtivelman, 1997), play crucial
roles in metastatic process via the regulation of cell survival under
anchorage-independent conditions. These findings suggest that
Bcl-2 alone is not likely to reflect anti-apoptotic activity in the
tumour cells. Furthermore, we consider it important to examine the
effect of Bcl-2 on the expression levels of specific inhibitor and
promoter genes of metastasis to address a possible mechanism for
enhanced metastatic potential of the Bcl-2-transfected cells more
completely. We also think it important to assess the effect of Bcl-2
on tumour cells in the circulation and early post-extravasation
phase in order to explore the actual apoptotic feature under
anchorage-independent conditions and provide clues underlying
the potential therapeutic strategy against early stage of metastasis.
For this purpose, as several previous studies suggested (Crowley et
al, 1993; Tsuchiya et al, 1993), it seems to be an attractive
approach to use easily detectable markers, such as radio isotope,
luciferase and chloramphenicol acetyltransferase.
In conclusion, our present results indicating enhancement of
malignant potential of bladder cancer cells in vivo by overexpres-
sion of Bcl-2 protein reveals a crucial role of anti-apoptotic
activity during tumour progression. Therefore, the expression of
Bcl-2 protein in bladder cancer cells may be a possible candidate
as a marker predicting development of bladder cancer.
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